Mid 2018 – Recap of Warning Letters, Import Alerts and Non-Compliances
Teva's struggling sterile plant hit with FDA warning letter - Skyland Analytics
Celltrion confident in quality of biosimilars despite FDA 483
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
UPDATE 2-Teva halts output at U.S. drug plant after FDA flags concerns
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
US FDA eases Teva headache with Ajovy approval
Biocon hit with Form 483
Teva Pharmaceuticals USA FDA 483, Aug 2009 | FDAzilla
FDA Form 483 shows Pfizer repeating same mistakes at troubled fill-finish plant | Fierce Pharma
Teva confirms US FDA warning letter for Hangzhou, China API plant
Teva Stops Production At US Plant After FDA Concerns: Report
QUALITY SYSTEM OBSERVATION 1 Procedures describing the handling ohvritten and oral complaints related to drug products are defic
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
FDA Regulation of Promotion & Advertising -- Part 4: FDA Enforcement…
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
Teva's struggling sterile plant hit with FDA warning letter - Skyland Analytics
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
Teva Recalls Drug Vials, Shuts Facility Over Mold Concerns - TheStreet
/cloudfront-us-east-2.images.arcpublishing.com/reuters/CCBS56SBRRKUDM7JEVVE3UOQEE.jpg "Teva halts output at U.S. drug plant after FDA flags concerns | Reuters")
Teva halts output at U.S. drug plant after FDA flags concerns | Reuters
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
